Litcius/Paper detail

Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant

Jonathan Douxfils, Charlotte Beaudart, Jean‐Michel Dogné

2023The Lancet24 citationsDOIOpen Access PDF

Topics & Concepts

AntagonistMedicineTachykinin receptor 1Internal medicinePharmacologyReceptorNeuropeptideSubstance PEstrogen and related hormone effectsMenopause: Health Impacts and TreatmentsPituitary Gland Disorders and Treatments
Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant | Litcius